This shows that PD-L1 CNG is a potential predictive biomarker of response to PD-1 blockade, as witnessed in patients with relapsed or refractory Hodgkin lymphoma, primary mediastinal large B cell lymphoma, and diffuse large B cell lymphoma [89]. Here, CD274 is linked to Hodgkins lymphoma.